BeiGene Ltd.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2010-01-01
- Employees
- 10K
- Market Cap
- $22.1B
- Website
- http://www.beigene.com
A Study to Evaluate the Effects of Phenytoin and Itraconazole on Sonrotoclax (BGB-11417) in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2024-08-07
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 30
- Registration Number
- NCT06543043
- Locations
- 🇺🇸
Quotient Sciences, Miami, Florida, United States
A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2024-08-06
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 75
- Registration Number
- NCT06540066
- Locations
- 🇺🇸
Usc Norris Comprehensive Cancer Center (Nccc), Los Angeles, California, United States
🇺🇸Washington University in St Louis, Saint Louis, Missouri, United States
🇺🇸Md Anderson Cancer Center, Houston, Texas, United States
A Study of BGB-R046 as Monotherapy and in Combination With Tislelizumab in Solid Tumors
- First Posted Date
- 2024-07-05
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 74
- Registration Number
- NCT06487858
- Locations
- 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China
🇨🇳Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
A Phase 1 Study of BGB-B2033, Alone or in Combination with Tislelizumab, in Participants with Advanced or Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2024-05-24
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 140
- Registration Number
- NCT06427941
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center Mskcc, New York, New York, United States
🇨🇳Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, Fujian, China
A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors
- First Posted Date
- 2024-05-21
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 62
- Registration Number
- NCT06422520
- Locations
- 🇺🇸
Florida Cancer Specialist Research Institute Lake Nona, Orlando, Florida, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035
- Conditions
- Interventions
- First Posted Date
- 2024-04-02
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 92
- Registration Number
- NCT06342713
- Locations
- 🇦🇺
Cmax Clinical Research, Adelaide, South Australia, Australia
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
- Conditions
- Interventions
- First Posted Date
- 2024-02-13
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 138
- Registration Number
- NCT06257264
- Locations
- 🇺🇸
Hoag Memorial Presbyterian, Newport, California, United States
🇦🇺Blacktown Cancer and Haematology Centre, Blacktown, New South Wales, Australia
🇨🇳Sun Yat Sen Memorial Hospital, Sun Yat Sen University (South), Guangzhou, Guangdong, China
BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 78
- Registration Number
- NCT06253195
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Sun Yat Sen Memorial Hospital, Sun Yat Sen University (South), Guangzhou, Guangdong, China
🇨🇳Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China
Study of BG-C9074 as Monotherapy and in Combination With Tislelizumab in Participants With Advanced Solid Tumors
- First Posted Date
- 2024-01-31
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 150
- Registration Number
- NCT06233942
- Locations
- 🇺🇸
Usc Norris Comprehensive Cancer Center (Nccc), Los Angeles, California, United States
🇺🇸University of Colorado Cancer Center, Aurora, Colorado, United States
🇺🇸Sidney Kimmel Comprehensive Cancer At Johns Hopkins, Baltimore, Maryland, United States
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
- Conditions
- Advanced Solid TumorAdvanced Breast CancerMetastatic Breast CancerHormone-receptor-positive Breast CancerHormone Receptor Positive Breast CarcinomaHormone Receptor Positive Malignant Neoplasm of BreastHER2-negative Breast CancerHormone Receptor Positive HER-2 Negative Breast CancerNon-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 79
- Registration Number
- NCT06120283
- Locations
- 🇺🇸
Sarah Cannon Research Institute (Scri) At Health One, Denver, Colorado, United States
🇺🇸Duke Cancer Center, Durham, North Carolina, United States
🇦🇺Peter Maccallum Cancer Centre, Melbourne, Victoria, Australia